In older patients with AF, low-dose edoxaban reduced stroke or systemic embolism without increasing major bleeding

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Atrial fibrillation increases stroke risk, particularly in the very elderly.
• Standard anticoagulant doses may pose a higher bleeding risk in elderly patients.
• Edoxaban is a direct oral anticoagulant used for stroke prevention.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose edoxaban in very elderly patients with atrial fibrillation.
• To compare low-dose edoxaban with standard doses in this specific patient group.

Main Methods:

• A randomized controlled trial was conducted.
• Participants were very elderly patients (≥80 years) with atrial fibrillation.
• Patients received either low-dose (15 mg once daily) or standard-dose (30 mg once daily) edoxaban.

Main Results:

• Low-dose edoxaban demonstrated non-inferiority to standard-dose edoxaban in preventing stroke or systemic embolism.
• The incidence of major bleeding was significantly lower in the low-dose edoxaban group compared to the standard-dose group.
• Hemorrhagic stroke events were also reduced in the low-dose group.

Conclusions:

• Low-dose edoxaban (15 mg) is an effective and safer alternative for stroke prevention in very elderly patients with atrial fibrillation.
• This dosage regimen balances efficacy with a reduced risk of bleeding complications in this frail population.